BPT Crunch

Companies on the Cutting Edge of Healthcare Innovations

back to Marketplace

Inovio Pharmaceuticals

Inovio Pharmaceuticals logo

Founded
1983
Patents
51
Clinical Trials
31
Publications
102

Inovio is revolutionizing vaccines to prevent and treat today&s;s cancers and challenging infectious diseases. Its SynCon vaccines, in combination with its proprietary electroporation delivery, are generating best-in-class immune responses, with therapeutic T-cell responses exceeding other technologies in terms of magnitude, breadth, and response rate. Human data to date have shown a favorable safety profile. Inovio&s;s lead vaccine, a therapeutic against HPV-caused pre-cancers and cancers, is in phase II. Other phase I and preclinical programs target prostate, breast, and lung cancers as well as HIV, influenza, malaria and hepatitis. Partners and collaborators include Roche, the University of Pennsylvania, Merck, NIH, HIV Vaccines Trial Network, National Cancer Institute, U.S. Military HIV Research Program, University of Southampton, US DEBT. of Homeland Security, University of Manitoba and PATH Malaria Vaccine Initiative

Become a Member to view additional information about this company

Posts Mentioning This Company

Biopharma Insights